Press Releases

December 16, 2025

NeuroSigma Completes $1 Million Investment into High-Volume Manufacturing Line for Second Generation Monarch eTNS® Device

​

November 18, 2025

NeuroSigma Launches Next-Generation Monarch Device for Pediatric ADHD After Successful Pilot Program

​

November 03, 2025

» NeuroSigma Announces New Publication Showing Real-Time Effects of External Trigeminal Nerve Stimulation (eTNS) on Brain Activity

 

June 10, 2025

» NeuroSigma Announces Notice of Allowance for Patent Protecting Monarch eTNS System in China

​​

April 30, 2025

» NeuroSigma Announces New Clinical Trial of Monarch eTNS System for Treatment of ADHD in Children with Fetal Alcohol Syndrome at UCLA

​

January 22, 2025

» NeuroSigma Announces Patent Application Protecting Use of Trigeminal Nerve Stimulation to Include Treatment of Dyslexia and Other Neurodevelopmental Disorders

​

January 13, 2025

» Clinical Trial of NeuroSigma's Monarch eTNS System for ADHD at King’s College London Completes Enrollment

​

December 11, 2024

» New Clinical Trial of eTNS for Pediatric ADHD to Commence at Denmark's Center for Evidence-Based Psychiatry

​

May 09, 2024

» NeuroSigma Announces Acceptance into 2024 Cohort of the KidsX Accelerator Program

​

January 18, 2024

» NeuroSigma Announces FDA Clearance of its Second-Generation Monarch eTNS System for Treating Pediatric ADHD

​

November 07, 2023

» NeuroSigma Announces FDA 510(k) Submission for Second Generation Monarch eTNS System

​

October 03, 2023

» NeuroSigma Announces HSA Approval of the Monarch eTNS System in Singapore

July 12, 2023» NeuroSigma Establishes Singapore Subsidiary

​

March 01, 2023

» NeuroSigma Announces New Telehealth Option for Patients and Caregivers Interested in eTNS for Pediatric ADHD

​

January 31, 2023

» NeuroSigma Announces Strategic Digital Marketing Partnership with Data360

​

November 08, 2022

» NeuroSigma Announces that Enrollment Commences in Two Large, Double-Blind Trials of eTNS for Pediatric ADHD

​

October 17, 2022

» NeuroSigma Announces Commercial Launch of The Monarch eTNS® System for the Treatment of Pediatric ADHD at Annual Meeting of the American Academy of Child and Adolescent Psychiatry

​

September 27,2022

» NeuroSigma Announces Receipt of Permanent HCPCS Codes from CMS for Monarch eTNS System

​

June 14, 2022

» NeuroSigma Announces That a Team Led by UCLA Researchers Receives NIH Grant to Conduct a Multicenter Trial of eTNS for Pediatric ADHD

​

April 7, 2022

» NeuroSigma Announces King’s College London Team Receives MHRA Approval to Commence Largest Clinical Trial of eTNS for Pediatric ADHD to Date

​

February 22, 2022

» NeuroSigma Receives FDA Breakthrough Device Designation for Monarch eTNS System®

​

January 25, 2022

» Ignis Therapeutics Licenses NeuroSigma eTNS Technology for ADHD in a Significant China Licensing Transaction

​

January 11, 2022

» NeuroSigma Announces Promotion of Dr. Colin Kealey to President

​

December 8, 2021

» NeuroSigma Announces a $5 Million Equity Investment by KT Corporation

​

June 14, 2021

» KT and NeuroSigma Announce Strategic Digital Health Partnership

​

March 11, 2021

» NeuroSigma Continues to Build a Substantial Global Bioelectronics Patent Portfolio

​

January 22, 2021

» NeuroSigma Successfully Obtains HCPCS Codes from CMS for the Monarch eTNS System